Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up

Background: The nine-valent human papillomavirus (9vHPV) vaccine protects against infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal 36-month Phase III immunogenicity study of 9vHPV vaccine in 9- to 15-year-old girls and boys was extended to assess long-ter...

Full description

Bibliographic Details
Main Authors: Sven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina, Punnee Pitisuttithum, Angels Ulied, Meera Varman, Pierre Van Damme, Edson Duarte Moreira, Jr., Daron Ferris, Stanley Block, Oliver Bautista, Nancy Gallagher, Jennifer McCauley, Alain Luxembourg
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Papillomavirus Research
Subjects:
Nine-valent human papillomavirus vaccine
Effectiveness
Immunogenicity
Long-term follow-up
Online Access:http://www.sciencedirect.com/science/article/pii/S2405852120300215

Internet

http://www.sciencedirect.com/science/article/pii/S2405852120300215

Similar Items